Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
09 Enero 2024 - 5:44AM
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
Reference is made to the stock exchange
announcement on 4 January 2024 regarding the conclusion of an
extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the
"Company") whereby the general meeting resolved, among other
things, an issuance of new preference class B shares in connection
with the NOK 144 million investment from Hofseth International AS
("HI").
Following the registration of the share capital
increase in the Norwegian Registry for Business Enterprises, the
Company's share capital is NOK 4,110,810.30 divided into 395,081,30
ordinary shares and 16,000,000 preference class B Shares.
The preference class B shares will be issued in
the VPS and delivered to HI on a separate ISIN than the Company's
ordinary shares.
For further information, please contact: Jon Olav Ødegård,
CEO at HBC Phone: +47 936 32 966 E-mail:
joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health
ingredient supplier and an incubator for new pharmaceutical drug
leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune
response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates
are focused on developing an oral treatment for inflammatory
disease driven by eosinophils (a type of white blood cell).
Clinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD ("smokers lung").
Other leads are focused on using the Company’s
bioactive peptides as a Medical Food for the protection of the
Gastro- Intestinal (GI) system against inflammation (including
ulcerative colitis and the orphan condition necrotizing
enterocolitis). The Company is founded on the core values of
sustainability, optimal utilization of natural resources and full
traceability. Through innovative and patent protected hydrolysis
technology, HBC can preserve the quality of the lipids, proteins
and calcium from fresh salmon off-cuts.
HBC's headquarters are in Ålesund, Norway with
offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
Hofseth Biocare Asa (LSE:0Q6H)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hofseth Biocare Asa (LSE:0Q6H)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024